Pulmonary vascular disease & thromboembolism
Pulmonary arterial hypertension treatment: an individual participant data network meta-analysis
Authors' conclusion
Drugs targeting the three traditional treatment pathways significantly improve outcomes in PAH, with significant treatment heterogeneity in patients with some comorbidities.
Study context
- Population
- Patients with pulmonary arterial hypertension (PAH) in Phase III RCTs submitted to the US Food and Drug Administration
- Participants
- 6,811 patients20 Phase III RCTs
- Comparison
- PAH treatment pathways vs placebo
- Outcome
- Change in 6 min walk distance
- Follow-up
- 12 or 16 weeks
Methodological detailscovariate-adjusted
- Covariate-adjusted
Pooled result
As reported in the abstract
6 min walk distance
β, m
- Endothelin + nitric oxide
- 43.7 (95% CI 32.9–54.4)
- Nitric oxide
- 29.4 (95% CI 22.6–36.3)
- Endothelin
- 25.3 (95% CI 19.8–30.8)
- Prostacyclin oral/inhaled
- 19.1 (95% CI 14.2–24.0)
- Prostacyclin intravenous/subcutaneous
- 24.4 (95% CI 15.1–33.7)
Further pooled results
Clinical worsening events
- Treatments significantly reduced the likelihood of clinical worsening events
Heterogeneity of treatment effects
- Significant heterogeneity by age, BMI, hypertension, DM and CAD
Original publication
Pulmonary arterial hypertension treatment: an individual participant data network meta-analysis. Eur Heart J. Published 28 February 2024. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →